Tasly Pharmaceutical Group Co Ltd (600535) — Financial Flexibility Index
Tasly Pharmaceutical Group Co Ltd (600535) has a Financial Flexibility Index of 0.24x as of December 2025. Free cash flow of CN¥669.91 Million (operating CF CN¥552.13 Million minus capex CN¥117.78 Million) represents 0% of total liabilities (CN¥2.79 Billion). Check Tasly Pharmaceutical Group Co Ltd investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Tasly Pharmaceutical Group Co Ltd Financial Flexibility Index (2001–2025)
Historical Financial Flexibility Index trend for Tasly Pharmaceutical Group Co Ltd across 25 annual periods. For the full cash flow conversion analysis, see Tasly Pharmaceutical Group Co Ltd cash flow conversion.
Annual Financial Flexibility Index for Tasly Pharmaceutical Group Co Ltd (2001–2025)
Year-by-year free cash flow to debt coverage for Tasly Pharmaceutical Group Co Ltd. Explore Tasly Pharmaceutical Group Co Ltd (600535) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.65x | CN¥1.81 Billion | CN¥1.42 Billion | CN¥2.79 Billion | ▼ -28.2% |
| 2024 | 0.90x | CN¥2.58 Billion | CN¥2.01 Billion | CN¥2.87 Billion | ▲ +11.7% |
| 2023 | 0.81x | CN¥3.24 Billion | CN¥2.58 Billion | CN¥4.02 Billion | ▲ +13.9% |
| 2022 | 0.71x | CN¥2.69 Billion | CN¥2.29 Billion | CN¥3.80 Billion | ▼ -32.3% |
| 2021 | 1.04x | CN¥3.37 Billion | CN¥2.80 Billion | CN¥3.23 Billion | ▲ +95.2% |
| 2020 | 0.54x | CN¥2.20 Billion | CN¥1.79 Billion | CN¥4.11 Billion | ▲ +169.8% |
| 2019 | 0.20x | CN¥2.41 Billion | CN¥1.68 Billion | CN¥12.15 Billion | ▲ +21.9% |
| 2018 | 0.16x | CN¥2.27 Billion | CN¥1.49 Billion | CN¥13.96 Billion | ▲ +757.5% |
| 2017 | -0.02x | CN¥-310.99 Million | CN¥-822.56 Million | CN¥12.56 Billion | ▼ -113.2% |
| 2016 | 0.19x | CN¥1.68 Billion | CN¥1.15 Billion | CN¥8.92 Billion | ▲ +34.5% |
| 2015 | 0.14x | CN¥1.08 Billion | CN¥340.00 Million | CN¥7.71 Billion | ▼ -19.9% |
| 2014 | 0.17x | CN¥1.37 Billion | CN¥616.76 Million | CN¥7.85 Billion | ▲ +5.0% |
| 2013 | 0.17x | CN¥1.01 Billion | CN¥346.17 Million | CN¥6.07 Billion | ▼ -32.1% |
| 2012 | 0.24x | CN¥803.33 Million | CN¥413.31 Million | CN¥3.28 Billion | ▲ +25.5% |
| 2011 | 0.20x | CN¥557.71 Million | CN¥135.14 Million | CN¥2.86 Billion | ▼ -29.5% |
| 2010 | 0.28x | CN¥561.18 Million | CN¥395.05 Million | CN¥2.03 Billion | ▼ -0.8% |
| 2009 | 0.28x | CN¥517.19 Million | CN¥400.39 Million | CN¥1.85 Billion | ▲ +0.9% |
| 2008 | 0.28x | CN¥374.72 Million | CN¥260.21 Million | CN¥1.36 Billion | ▼ -26.8% |
| 2007 | 0.38x | CN¥422.78 Million | CN¥221.55 Million | CN¥1.12 Billion | ▲ +46.8% |
| 2006 | 0.26x | CN¥395.97 Million | CN¥140.56 Million | CN¥1.54 Billion | ▼ -40.2% |
| 2005 | 0.43x | CN¥511.22 Million | CN¥214.90 Million | CN¥1.19 Billion | ▼ -38.0% |
| 2004 | 0.69x | CN¥572.88 Million | CN¥203.27 Million | CN¥826.42 Million | ▲ +2.9% |
| 2003 | 0.67x | CN¥387.74 Million | CN¥59.00 Million | CN¥575.74 Million | ▼ -48.6% |
| 2002 | 1.31x | CN¥332.31 Million | CN¥206.22 Million | CN¥253.70 Million | ▲ +124.5% |
| 2001 | 0.58x | CN¥203.12 Million | CN¥83.77 Million | CN¥348.19 Million | — |